4-(1,4-dihydro-1,4-epioxido-tribenzo[a,c,e]cyclohepten-9-ylidene)-1-methyl-piperidine | 61032-39-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 二苯并环庚烯
• 英文名称: 4-(1,4-dihydro-1,4-epioxido-tribenzo[a,c,e]cyclohepten-9-ylidene)-1-methyl-piperidine
• 英文别名: 1-Methyl-4-(1,4-dihydro-1,4-epoxy-9H-tribenzo[a,c,e] cycloheptene-9-ylidene)piperidine；1-methyl-4-(1,4-dihydro-1,4-epoxy-9H-tribenzo[a,c,e]cyclohepten-9-ylidene)-piperidine；1-methyl-4-(20-oxapentacyclo[15.2.1.02,16.03,8.010,15]icosa-2(16),3,5,7,10,12,14,18-octaen-9-ylidene)piperidine
• CAS: 61032-39-1
• 化学式: C₂₅H₂₃NO
• 分子量: 353.464
• InChiKey: VMXFATFPJHNDDN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  27
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(1,4-dihydro-1,4-epioxido-tribenzo[a,c,e]cyclohepten-9-ylidene)-1-methyl-piperidine 在 四苯基环戊二烯酮 作用下， 以 xylene 为溶剂， 生成 4-dibenzo[3,4;6,7]cyclohepta[1,2-c]furan-8-ylidene-1-methyl-piperidine
  参考文献：
  名称：

  A comparison of the antiserotonin, antihistamine, and anticholinergic activity of cyproheptadine with analogs having furan nuclei fused to the 10,11-vinylene bridge

  摘要：

  A series of cyproheptadine derivatives having furan nuclei fused to the 10,11-vinylene bridge has been prepared. None of the compounds retain the potent antiserotonin and antihistaminic actions of cyproheptadine. 1-methyl-4-(1-methyl-8H-dibenzo[a,e]furo[3,4-c]cyclohepten-8-ylidene)piperidine (7), 1-methyl-4-(1,3-dihydro-1-oxo-8H-[3,4:6,7]cycloheptal[1,2-c]furan-8-ylidene)piperidine (10), and its reduction product 11 retained the peripheral anticholinergic activity of cyproheptadine.

  DOI：

  10.1021/jm00216a020
• 作为产物：
  描述：

  1-methyl-4-(10-bromo-5H-dibenzo[a,d] cyclohepten-5-ylidene)-piperidine 在 盐酸 作用下， 以 呋喃 、 乙醇 、 叔丁醇 为溶剂， 生成 4-(1,4-dihydro-1,4-epioxido-tribenzo[a,c,e]cyclohepten-9-ylidene)-1-methyl-piperidine
  参考文献：
  名称：

  10,11-Furo-derivatives of cyproheptadine

  摘要：

  本文披露了赛庚啶的10,11-呋喃和10,11-双-(羟基烷基)衍生物，具有抗胆碱能活性，但减弱或消除了抗血清素和抗组胺活性。还披露了制备这种化合物的过程；包含这种化合物的药物组合物以及包含这种化合物和组合物的治疗方法。

  公开号：

  US03974285A1

文献信息

• 10,11-Bis-(hydroxyalkyl) derivatives of cyproheptadine
  申请人：Merck & Co., Inc.

  公开号：US04044143A1

  公开（公告）日：1977-08-23

  10,11-Furo and 10,11-bis-(hydroxyalkyl) derivatives of cyproheptadine are disclosed having anticholinergic activity but with diminished or eliminated antiserotonin and antihistamine activity. Also disclosed are processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds, and methods of treatment comprising administering such compounds and compositions.

  本文披露了10,11-Furo和10,11-双-(羟基烷基)环己嗪的衍生物，具有抗胆碱能活性，但具有减弱或消除的抗血清素和抗组胺活性。还披露了制备这种化合物的过程；包含这种化合物的制药组合物，以及包括给予这种化合物和组合物的治疗方法。
• US3974285A
  申请人：——

  公开号：US3974285A

  公开（公告）日：1976-08-10
• US4044143A
  申请人：——

  公开号：US4044143A

  公开（公告）日：1977-08-23
• A comparison of the antiserotonin, antihistamine, and anticholinergic activity of cyproheptadine with analogs having furan nuclei fused to the 10,11-vinylene bridge
  作者：David C. Remy、Andrew W. Raab、Kenneth E. Rittle、Edward L. Engelhardt、Alexander Scriabine、Victor J. Lotti

  DOI：10.1021/jm00216a020

  日期：1977.6

  A series of cyproheptadine derivatives having furan nuclei fused to the 10,11-vinylene bridge has been prepared. None of the compounds retain the potent antiserotonin and antihistaminic actions of cyproheptadine. 1-methyl-4-(1-methyl-8H-dibenzo[a,e]furo[3,4-c]cyclohepten-8-ylidene)piperidine (7), 1-methyl-4-(1,3-dihydro-1-oxo-8H-[3,4:6,7]cycloheptal[1,2-c]furan-8-ylidene)piperidine (10), and its reduction product 11 retained the peripheral anticholinergic activity of cyproheptadine.
• 10,11-Furo-derivatives of cyproheptadine
  申请人：Merck & Co., Inc.

  公开号：US03974285A1

  公开（公告）日：1976-08-10

  10,11-Furo and 10,11-bis-(hydroxyalkyl) derivatives of cyproheptadine are disclosed having anticholinergic activity but with diminished or eliminated antiserotonin and antihistamine activity. Also disclosed are processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds, and methods of treatment comprising administering such compounds and compositions.

  本文披露了赛庚啶的10,11-呋喃和10,11-双-(羟基烷基)衍生物，具有抗胆碱能活性，但减弱或消除了抗血清素和抗组胺活性。还披露了制备这种化合物的过程；包含这种化合物的药物组合物以及包含这种化合物和组合物的治疗方法。